This inventor holds 1 USPTO granted patent and 3 published patent applications and 1 EPO patent. Top assignee: Ucl Business Plc. Active years: 2014.
Company Filing History:
Years Active: 2014
Title: Max Topp: Innovator in T-Cell Receptor Technology
Introduction
Max Topp is a notable inventor based in Wuerzburg, Germany. He has made significant contributions to the field of immunotherapy, particularly through his work on T-cell receptors. His innovative approach has the potential to advance treatments for diseases associated with the Epstein Barr Virus.
Latest Patents
Max Topp holds a patent for a T-cell receptor (TCR) that binds to a peptide from latent membrane protein 2 (LMP-2) from the Epstein Barr Virus (EBV). This TCR specifically recognizes the amino acid sequence CLGGLLTMV (SEQ ID No. 1) when presented by a major histocompatibility complex (MHC) molecule. The patent also includes a nucleotide sequence encoding this TCR, a vector comprising the nucleotide sequence, and its application in producing EBV-specific T-cells. Furthermore, the invention outlines the use of these EBV-specific T-cells for cellular immunotherapy.
Career Highlights
Max Topp is associated with UCL Business Plc, where he continues to develop his research and innovations. His work has been instrumental in advancing the understanding of T-cell receptors and their applications in medical therapies.
Collaborations
Max Topp has collaborated with esteemed colleagues such as Hans Josef Stauss and Shao-An Xue. Their combined expertise has contributed to the advancement of research in T-cell receptor technology.
Conclusion
Max Topp's innovative work in T-cell receptor technology represents a significant advancement in the field of immunotherapy. His contributions have the potential to improve treatment options for patients affected by the Epstein Barr Virus.